[1]
|
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
Advances in Therapy,
2023
DOI:10.1007/s12325-023-02525-x
|
|
|
[2]
|
Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data
Current Oncology,
2023
DOI:10.3390/curroncol30070484
|
|
|
[3]
|
Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers
Journal of Medical Economics,
2020
DOI:10.1080/13696998.2019.1696349
|
|
|
[4]
|
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
Clinical Drug Investigation,
2020
DOI:10.1007/s40261-020-00922-6
|
|
|
[5]
|
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Journal of Medical Economics,
2019
DOI:10.1080/13696998.2019.1609485
|
|
|
[6]
|
Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands
Anti-Cancer Drugs,
2018
DOI:10.1097/CAD.0000000000000628
|
|
|
[7]
|
Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States
Journal of Managed Care & Specialty Pharmacy,
2017
DOI:10.18553/jmcp.2017.23.2.184
|
|
|
[8]
|
Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review
PharmacoEconomics,
2017
DOI:10.1007/s40273-017-0517-1
|
|
|
[9]
|
Use of chronolithotherapy for better individual healthcare and welfare
Journal of Systems Science and Systems Engineering,
2017
DOI:10.1007/s11518-017-5336-6
|
|
|
[10]
|
Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)
The Oncologist,
2017
DOI:10.1634/theoncologist.2016-0272
|
|
|